Abstract
The clinical utility and diagnostic yield of exome sequencing (ES) and multi-gene panel tests in patients with suspected genetic conditions is well-established. Despite this, many patients continue to face barriers to clinical genetic testing including insurance denials. In most cases, it is impossible to know how many patients whose clinical genetic testing is denied by insurance may have an actionable variant because they never receive access to testing. As a result, little research approached this issue.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
